NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.
The dual orexin receptor antagonist suvorexant was effective in managing VMS*-associated insomnia among women in midlife, with further benefits for self-reported night-time, but not daytime, VMS, according to data presented at NAMS 2020.
Use of the self-administered TX-004HR – an applicator-free, ultra-low-dose, 17β-oestradiol softgel vaginal insert – led to significant improvements in the symptoms of vulvovaginal atrophy (VVA) such as moderate-to-severe dyspareunia and vaginal dryness in postmenopausal women aged >60 years, according to updated results from the phase III REJOICE trial presented at NAMS 2020.
One way how hormone therapy with oestradiol may slow the progression of atherosclerotic cardiovascular disease (CVD) in postmenopausal women is through the reduction of inflammatory biomarkers, according to the ELITE* study presented at the NAMS 2020 Annual Meeting.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.